Wegovy
PRODUCT · 5 article mentions
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardiovascular events. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management, weight loss, and the treatment of metabolic-associated steatohepatitis.
Wikipedia: https://en.wikipedia.org/wiki/Semaglutide
Wikidata: Q133859283
Recent mentions
- The FDA approves a new obesity pill, giving patients another option
- Biggest winner of the amended Microsoft-OpenAI deal — plus, mixed news for Eli Lilly
- Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
- FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
- Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator